Malabsorption syndrome

disease
On this page

Also known as malabsorption

Summary

Malabsorption syndrome (MONDO:0020598) is a disease (an umbrella term covering 9 Mondo subtypes) and 30 clinical trials. Top therapeutic interventions include lidocaine and tannic acid. A subtype of intestinal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Umbrella term: 9 Mondo subtypes
  • Clinical trials: 30

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemalabsorption syndrome
Mondo IDMONDO:0020598
EFOEFO:0009554
MeSHD008286
NCITC3214
SNOMED CT32230006
UMLSC0024523
MedGen44256
Is cancer (heuristic)no

Also known as: malabsorption · malabsorption syndrome

Disease family

This is a subtype of intestinal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderintestinal disordermalabsorption syndrome

Related subtypes (57): intestinal atresia, steatorrhea, angiodysplasia of intestine, endometriosis of intestine, hypertrophic pyloric stenosis, mucocele of appendix, gastroenteritis, diverticulitis, intestinal obstruction, postgastrectomy syndrome, chronic intestinal vascular insufficiency, bowel dysfunction, irritable bowel syndrome, Whipple disease, inflammatory bowel disease, intestinal polyp, necrotizing enterocolitis, intestinal perforation, neurogenic bowel, pneumatosis cystoides intestinalis, volvulus of midgut, abetalipoproteinemia, aplasia cutis congenita-intestinal lymphangiectasia syndrome, trichohepatoenteric syndrome, protein-losing enteropathy, chronic diarrhea with villous atrophy, Satoyoshi syndrome, glucose-galactose malabsorption, congenital diarrhea 7 with exudative enteropathy, chronic atrial and intestinal dysrhythmia, congenital enterocyte heparan sulfate deficiency, short bowel syndrome, intractable diarrhea-choanal atresia-eye anomalies syndrome, solitary rectal ulcer syndrome, NK-cell enteropathy, chronic intestinal failure, intestinal lymphangiectasia, refractory celiac disease, eosinophilic gastrointestinal disease, cryptogenic multifocal ulcerous stenosing enteritis, chronic enteropathy associated with SLCO2A1 gene, cytosolic phospholipase-A2 alpha deficiency associated bleeding disorder, malakoplakia, ischemic bowel disorder, intestinal neoplasm, intestinal motility disease, 4-hydroxyphenylacetic aciduria, parasitic intestinal disorder, Aeromonas hydrophila intestinal disease, large intestine disorder, small intestine disorder, primary desmosis coli, isolated mesenteric vein thrombosis, collagenous sprue, visceral leiomyopathy, African degenerative, intestinal dysmotility syndrome, intestinal fistula

Subtypes (9): tropical sprue, intestinal disaccharidase deficiency, celiac disease, blind loop syndrome, hereditary folate malabsorption, lysine malabsorption syndrome, idiopathic malabsorption due to bile acid synthesis defects, autoimmune enteropathy, lactose intolerance

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
TeduglutideApproved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 30.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified24
PHASE33
PHASE22
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00521703PHASE3COMPLETEDEvaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children
NCT00662675PHASE3COMPLETEDA Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
NCT02247102PHASE3UNKNOWNInvestigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose or Sucrose in Infants
NCT06904872PHASE2RECRUITINGSafety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
NCT03644069PHASE2UNKNOWNA Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)
NCT03543540PHASE1COMPLETEDBioequivalence Study of Nexvax2 in Subjects With Celiac Disease
NCT03530852Not specifiedRECRUITINGA 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
NCT05209568Not specifiedRECRUITINGImmune Responses to Gluten
NCT05635747Not specifiedENROLLING_BY_INVITATIONA 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
NCT06858631Not specifiedACTIVE_NOT_RECRUITINGIMPact of AerobiC Exercise in Addition to Nutritional Treatment on Quality of Life After Pancreatectomy
NCT06877923Not specifiedRECRUITINGElemental 028 Extra Case Studies
NCT07366151Not specifiedNOT_YET_RECRUITINGLong-term Health Outcomes of Screen Detected and Potential Celiac Disease Patients
NCT00138879Not specifiedCOMPLETEDCitrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn’s Disease Patients
NCT00163813Not specifiedUNKNOWNThe Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study
NCT00456729Not specifiedCOMPLETEDMalabsorption as a Cause of Iron Treatment Failure in Infants
NCT00816842Not specifiedCOMPLETEDPlasma Citrulline Concentration in Tropical Enteropathy
NCT00872092Not specifiedCOMPLETEDValidation of Breath Tests in Diagnosing Small Bowel Bacterial Overgrowth
NCT01141998Not specifiedCOMPLETEDVitamin D Substitution for Patients With Chronic Pancreatitis and Malabsorption
NCT01862510Not specifiedCOMPLETEDDetection of Celiac Disease in Patients With Hypothyroidism
NCT01900288Not specifiedCOMPLETEDHome Parenteral Nutrition (HPN) Families’ Mobile Distance Connections to Care Research
NCT02590120Not specifiedCOMPLETEDEnteral Nutrition and Amino Acid Absorption
NCT02750787Not specifiedCOMPLETEDUse of a Peptide-based Formula in an Adult Population
NCT02953223Not specifiedCOMPLETEDA Study to Monitor the Use of an Amino Acid-Based Infant Formula
NCT02987569Not specifiedCOMPLETEDTeen and Young Adult Connections for Support From Multidisciplinary Professionals & Peers
NCT03140371Not specifiedCOMPLETEDHigh Energy High Protein Peptide Feed Study
NCT03462979Not specifiedSUSPENDEDEffects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease
NCT03897517Not specifiedUNKNOWNEffect of Proprietary Botanical Blend on Glycemic Control and Post-prandial Carbohydrate Absorption
NCT04309149Not specifiedCOMPLETEDMarket Research - Acceptability Study for a Range of MCT Products
NCT04309214Not specifiedCOMPLETEDMarket Research - Acceptability Study for New MCT Fat Products
NCT04777682Not specifiedUNKNOWNIntestinal Ultrasound Versus Double Balloon Enteroscopy (DBE) in Diagnosis of Malabsorption Syndrome

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
LIDOCAINE41
TANNIC ACID41
CHEMBL303920101
CHEMBL519326201